Past research

Over the past 25 years, the Leukaemia Foundation has committed more than $61 million towards blood cancer research in Australia.

Currently we have 26 grants with a total value of $11.1 million (as at December 2025)

MM24 – Amyloidosis International Clinical Trial, Dr Simon Gibbs. (Trials Enabling Program)
CLARIFY Clinical Trial – risk-adapted CAR T-cell therapy for ULTRArisk patients with diffuse large B-cell lymphoma, Professor Maher Gandhi, Mater Research. (Clinical trial)
Impact of frailty on treatment and healthcare: improving quality of life for older myelodysplastic neoplasms/acute myeloid leukaemia patients, Dr Devendra Hiwase, SAHMRI. (Strategic Ecosystem Research Program)
An age-old problem: the role of sensitive bone marrow stromal cells in monoclonal gammopathy of undetermined significance to multiple myeloma progression, Dr Kate Vandyke, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
Investigating mechanisms of disease development and new therapies in acute myeloid leukaemia with high-risk genetic alterations, Dr Vajiranee Malalasekera, Monash University. (PhD scholarship)
Therapeutic targeting of T-cell acute lymphoblastic leukaemia using an AKR1C3-activated prodrug, Professor Richard Lock, Children’s Cancer Institute. (Translational Research Program)
Investigation of T-cell versus T-cell biology in cutaneous T-cell lymphomas, cellular immunotherapy and extracorporeal photopheresis, Dr Jessica Elliott, Melbourne Health. (PhD scholarship)
Novel measurable residual disease – directed therapies in acute myeloid leukaemia, Dr Sun Loo, Peter MacCallum Cancer Centre. (PhD scholarship)
“Off-the-shelf” CAR NK-cells engineered for enhanced activity against acute myeloid leukaemia, Dr David Bishop, University of Sydney. (Strategic Ecosystem Research Program)
Therapeutically targeting novel vulnerabilities in acute myeloid leukaemia, Dr Jenny Wang, University of Sydney. (Strategic Ecosystem Research Program)
Gut microbiome in acute lymphoblastic leukaemia, Professor Deborah White, SAHMRI. (Strategic Ecosystem Research Program)
Using mutographs to define the molecular landscape and cell of origin of Waldenstrom’s Macroglobulinaemia, Dr Gareth Morgan, International Waldenstrom’s Macroglobulinaemia Foundation. (Strategic Ecosystem Research Program)
Targeted inhibition of myeloperoxidase: a new therapeutic strategy to prevent multiple myeloma disease progression, Dr Bill Panagopoulos, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
Non-canonical PI3K targeting – novel therapies to exploit the lipid dependency of chronic lymphocytic leukaemia, Dr Lauren Thurgood, Flinders University. (Priority-driven Collaborative Cancer Research Scheme)
Therapeutically targeting novel vulnerabilities in acute myeloid leukaemia, Dr Ashwin Unnikrishnan, University of NSW. (Strategic Ecosystem Research Program)
Understanding molecular determinants of immune evasion to CAR T, Professor Mark Dawson, University of Melbourne. (Translational Research Program)
Skipping beyond chemotherapy: therapeutically targeting aberrant RNA splicing in acute myeloid leukaemia, Dr Ashwin Unnikrishnan, University of NSW. (Breakthrough Fellowship)
Igniting progress in B-acute lymphoblastic leukaemia: elucidating resistance mechanisms and pioneering therapies, Dr Ashley Ng, WEHI. (Breakthrough Fellowship)
Identification of factors in the pre- and post-treatment tumour microenvironment that impair the efficacy of CD19 CAR T immunotherapy for diffuse large B-cell lymphoma, Dr Helen Cashman, University of Sydney. (PhD scholarship)
Applying novel single-cell multiomics to uncover why resistance to targeted therapies for blood cancers emerges, Dr Eric Wenlong Li, WEHI. (PhD scholarship)
Investigating the apoptosis-unrelated functions of MCL-1 in the context of haematological malignancy, organ development and inhibitor toxicity, Damian D’Silva, WEHI. (PhD scholarship)
Improving patient-reported outcomes in patients with lymphoma, Dr Elizabeth Goodall, Olivia Newton John Cancer Research Institute, Austin Health. (PhD scholarship)
Understanding the response to bispecific T-cell engager therapy in large B-cell lymphoma, Dr Sean Harrop, Peter MacCallum Cancer Institute. (PhD scholarship)
Understanding how acute myeloid leukaemia resists menin inhibitor treatment, Dr Rithin Nedumannil, Peter MacCallum Cancer Institute. (PhD scholarship)
Centre for Blood Transplant and Cellular Therapy, Professor David Gottlieb, University of Sydney. (Strategic Ecosystem Research Program)
CLL12 AETHER Clinical Trial, Professor Philip Thompson and Professor Stephen Opat. (ALLG – Trials Enabling Program)
MoST-LLy – Blood Cancer Genomics Trial, Professor Steven Lane and Professor Hamish Scott, QIMR Berghofer. (Clinical trial)

Completed research projects

A new precision medicine approach for curing chronic myeloid leukaemia, Dr Ilaria Pagani and Professor Timothy Hughes, SAHMRI. (Strategic Ecosystem Research Program)
Precision molecular diagnostics of single cells by imaging flow cytometry, Associate Professor Kathy Fuller, University of Western Australia. (Strategic Ecosystem Research Program)
Manipulating vascular environments to alleviate cancer therapy side-effects, Associate Professor Ingrid Winkler, The University of Queensland. (Strategic Ecosystem Research Program)
Optimising azacitidine responsiveness in myelodysplasia and acute myeloid leukaemia, Professor John Pimanda, University of NSW. (Strategic Ecosystem Research Program)
Accelerating genome ageing to predict and prevent leukaemia, Associate Professor Ian Majewski, WEHI. (Strategic Ecosystem Research Program)
Deep profiling of multiple myeloma during selinexor treatment to predict and improve drug responses, Dr Charis Teh, WEHI. (Strategic Ecosystem Research Program)
Examining the pathogenic bone marrow microenvironment, haematopoietic stem cell stress and targeting clonal evolution to prevent development of leukaemia in predisposed individuals, Associate Professor Anna Brown, University of South Australia. (Strategic Ecosystem Research Program)

The Centre for Blood Transplant and Cell Therapy project, Dr Wei Jiang, Western Sydney Local Health District. (Rebecca Gumley Fellowship)
Elucidating leukaemia cell plasticity in resistance to targeted therapy, Dr Rachel Thijssen, WEHI. (Priority-driven Collaborative Cancer Research Scheme)
Improving the safety and efficacy of CAR T-cell therapies, Associate Professor Melissa Call, WEHI. (Strategic Ecosystem Research Program)
SA Genomics Health Alliance, Haematological Malignancies Node – new rapid acute myeloid leukaemia and myeloproliferative neoplasm next generation sequencing panel, Associate Professor Anna Brown, University of South Australia. (Strategic Ecosystem Research Program)
Improving CAR T-cell therapy outcomes for patients with aggressive lymphoma and multiple myeloma, Associate Professor Jane Oliaro, Peter MacCallum Cancer Centre. (Translational Research Program)
Determining the risk factors and consequences of clonal haematopoiesis of indeterminate potential in the healthy elderly, Dr Jasmine Singh, Monash University. (PhD scholarship)
Immune reconstitution following reduced-intensity conditioning allogeneic stem cell transplantation, Dr Ray Mun Koo, Melbourne Health. (PhD scholarship)

Developing first translational model of paediatric graft versus host disease to evaluate prophylactic efficacy of faecal microbiota transplantation, Dr Hannah Wardill, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
Overcoming immunosuppression in B-cell lymphoma, Dr Kyohei Nakamura, QIMR Berghofer. (Priority-driven Collaborative Cancer Research Scheme)
AMLM26 – Phase 1B/2 study investigating novel therapies to target early relapse and clonal evolution as pre-emptive therapy in acute myeloid leukaemia (INTERCEPT): a multi-arm, precision-based, recursive, platform trial, Professor Andrew Wei. (ALLG – Trials Enabling Program)
NHL30 PETReA COVID vaccination study, Professor Judith Trotman. (ALLG – Trials Enabling Program)
SerOZNET – SARS-CoV-2 post-vaccine surveillance studies in Australian adults with cancer, Associate Professor Nada Hamad and Dr Michael Leahy, St Vincent’s Hospital and Royal Perth Hospital. (ALLG – Trials Enabling Program)
Amyloidosis tandem mass spectrometry, Professor Peter Mollee, PA Research Foundation. (Strategic Ecosystem Research Program)
A new precision medicine approach for achieving treatment-free remission in chronic myeloid leukaemia, Dr Ilaria Pagani, SAHMRI. (Strategic Ecosystem Research Program)
Targeting DCAF1 as a novel treatment strategy for therapy resistant multiple myeloma, Associate Professor Lev Kats, University of Melbourne. (Translational Research Program)
Optimising azacytidine responsiveness in myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, Professor John Pimanda, University of NSW. (Translational Research Program)
Identifying subclones in early phase myeloproliferative neoplasms that drive progression and leukaemic transformation, Dr Julian Grabek, QIMR Berghofer. (PhD scholarship)
Targeting the cancer-immune crosstalk in acute myeloid leukaemia, Basit Salik, QIMR Berghofer. (PhD scholarship)

New therapeutic strategies for children with high-risk leukaemia by dissecting and targeting the bone marrow microenvironment, Associate Professor Laurence Cheung, Curtin University. (Priority-driven Collaborative Cancer Research Scheme)
Developing new tests to identify which individuals with smouldering myeloma are at risk of developing multiple myeloma, Dr Melissa Cantley, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
Multiomic analysis of DNA, RNA and epigenomic networks for prognostication and novel target identification in Waldenstom’s macroglobulinemia, Dr Zachary Hunter, Dana-Farber Cancer Institute. (Strategic Ecosystem Research Program)
AMLM23 – placebo-controlled study to compare the event free survival of patients receiving ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome, Professor Paula Marlton. (ALLG – Trials Enabling Program)
AMLM24 – a study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy, Professor Andrew Wei. (ALLG – Trials Enabling Program)
Personalised metabolic targeting of epigenetic acute myeloid leukaemia mutations, Professor Ravindra Majeti and Professor Daniel Thomas, Stanford University and University of Adelaide. (Translational Research Program)
Optimal immunoglobulin replacement strategies in patients with acquired hypogammaglobulinaemia secondary to haematological malignancies, Dr Khai Li Chai, Monash University. (PhD scholarship)
Antifungal management optimization in hematological malignancy and hematopoietic stem cell transplantation protocol overview, Julian Lindsay, Peter MacCallum Cancer Centre. (PhD scholarship)
Development of improved biomarkers and targeted therapies for myeloproliferative neoplasms, Dr Liesl Butler, Monash University. (PhD scholarship)

Targeting multidrug resistance protein 1 enhances the efficacy of SMAC-mimetic-based therapy in acute myeloid leukaemia, Dr Gabriela Brumatti, WEHI. (Priority-driven Collaborative Cancer Research Scheme)
Increasing drug delivery and improving the quality of life for multiple myeloma patients, Dr Kate Vandyke, SAHMRI. (Priority-driven Collaborative Cancer Research Scheme)
Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research, Dr Laura Bray, QUT. ) (Priority-driven Collaborative Cancer Research Scheme)
Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children, Dr Michelle Henderson, Children’s Cancer Institute. (Priority-driven Collaborative Cancer Research Scheme)
Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells, Dr Jenny Wang, Children’s Cancer Institute. (Priority-driven Collaborative Cancer Research Scheme)
Characterisation of a novel DCAF factor as a blood cancer therapy, Professor Jake Shortt, Monash University. (Strategic Ecosystem Research Program)
The role of the bone marrow microenvironment in the myeloma plasma cell dormancy and reactivation – towards a cure for multiple myeloma, Professor Andrew Zannettino, University of Adelaide. (Strategic Ecosystem Research Program)
Understanding the pathways that regulate transformation of normal stem cells to myelodysplastic syndromes and acute leukaemia, Professor Steven Lane, QIMR Berghofer. (Strategic Ecosystem Research Program)
Precision medicine in acute lymphoblastic leukaemia, Professor Deborah White, SAHMRI. (Strategic Ecosystem Research Program)
Deep profiling of multiple myeloma and acute lymphoblastic leukaemia for targeted therapies, Professor Daniel Gray, WEHI. (Strategic Ecosystem Research Program)
NHL30 PETReA: phase 3 evaluation of PET-guided, response-adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma, Professor Judith Trotman. (ALLG – Trials Enabling Program)

Novel drug for treatment of Burkitt’s lymphoma, Professor Andreas Strasser and Dr Gemma Kelly, WEHI. (Strategic Ecosystem Research Program)
SA Genomics Health Alliance, Haematological Malignancies Node, Associate Professor Anna Brown, University of South Australia. (Strategic Ecosystem Research Program)
Clinical, genomic and molecular determinants of outcomes in patients with bone marrow failure syndromes, Dr Lucy Fox, Monash University. (Strategic Ecosystem Research Program)
Establishing a new prognostic score for follicular lymphoma to inform therapeutic decision making and improve patient outcomes, Professor Maher Gandhi, University of Queensland. (Strategic Ecosystem Research Program)

HD10 – Hodgkin lymphoma clinical trial: treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD, Professor Mark Hertzberg. (ALLG – Trials Enabling Program)

Obinutuzumab (CLL7 study), Professor Stephen Mulligan, Royal North Shore Hospital, ALLG. (Grant-in-aid)
Survivorship in blood cancer, Associate Professor Pam McGrath, University of Notre Dame Australia. (Grant-in-aid)
How do the functional interaction between pro-survival MCL-1, proapoptotic BIM and the tumour suppressor P53 affect the development, sustained growth and therapeutic responses of leukaemia and lymphoma? Dr Stephanie Gradbow, WEHI. (Postdoctoral fellowship)
Epigenetic targeting of leukaemia stem cells, Dr Omer Gilan, University of Melbourne. (Postdoctoral fellowship)
Designing protein-protein interaction modulator for anti-leukaemia therapy, Dr Jessica Holien, St Vincent’s Institute of Medical Research. (Postdoctoral fellowship)
The involvement of class I and class II mutations in the onset and progression of acute myeloid leukaemia, Dr Andrea Newbold, University of Melbourne. (Postdoctoral fellowship)
Net humoral immunity and its impact on outcome in lymphoma, Dr Colm Keane, The University of Queensland. (Career establishment grant)
Investigating the role of BLIMP1/PRDM1 and XBP1 as potential tumour suppressors in multiple myeloma, Dr Pasquale Fedele, WEHI. (Clinical PhD scholarship)
Generating genetically modified CAR T-cells to treat haematological malignancies, Dr Ming-Celine Dubosq, University of Sydney. (Clinical PhD scholarship)
Targeting regulator of natural killer cell homeostasis in leukaemia immunotherapy, Rebecca Delconte, WEHI. (PhD scholarship)
What factors drive immune response in acute myeloid leukaemia? Rebecca Austin, QIMR Berghofer. (PhD scholarship)
Assessing the efficacy and toxicities of a novel MCL-1 inhibitor in mouse and human pre-clinical models, Margs Brennan, WEHI. (PhD scholarship)
Circulating tumour DNA for monitoring treatment responses and resistance in chronic lymphocytic leukaemia, Elise Wallach, University of Melbourne. (PhD scholarship)
Visualising the mechanism of action of epigenetic therapies in myelodysplastic syndrome, Dean Tyler, University of Melbourne. (PhD scholarship)
A genomic approach to understanding clonal evolution and disease transition in myeloma, Ankit Dutta, University of Adelaide. (PhD scholarship)

Accurate BCR-ABL1 compound mutation detection to examine their role in drug resistance, Dr Wendy Parker and Dr David Yeung, University of SA. (Grant-in-aid)
SF3B1-associated back-splicing of genes in myelodysplasia and chronic lymphocytic leukaemia, Dr Timothy Mercer, Garvan Institute of Medical Research. (Grant-in-aid)
Combining vaccination and antibody-based immunotherapy to treat B-cell lymphomas, Dr Stephen Mattarollo, Diamantina Institute. (Grant-in-aid)
IL-17 mediated mobilisation of haematopoietic stem and progenitor cells, Professor Steven Lane, QIMR Berghofer. (Grant-in-aid)
Development of a genetic risk score that predicts response to hypomethylating agents in myelodysplastic syndromes, Dr Meaghan Wall, St Vincent’s Hospital. (Grant-in-aid)
Developing a national survivorship care plan for survivors of childhood blood cancer, Dr Jordana McLoone, University of NSW. (Grant-in-aid)
Exploring cic-regulatory mutation in acute myeloid leukaemia, Dr Jason Wong, Lowy Cancer Research Centre, University of NSW. (Grant-in-aid)
Genomic profiling to define therapy resistance mechanisms in myeloid leukaemia, Associate Professor Ian Majweski, WEHI. (Grant-in-aid)
Thrombopoietin signalling in lymphoid cancer, Dr Emma Josefsson and Dr Kylie Mason, WEHI. (Grant-in-aid)
Targeting IL-7 signalling pathway in T-Cell acute lymphoblastic leukaemia, Dr Cedric Tremblay, Monash University. (Grant-in-aid)
The role of C-Cbl in regulation the development of acute myeloid leukaemia, Associate Professor Carolyn Grove, University of WA. (Grant-in-aid)
Impact of deregulated HOXA1 in myelodysplastic syndromes, Dr Shuh Ying Tan, St Vincent’s Institute. (Clinical PhD scholarship)
Combination therapies with the novel POL I transcription inhibitor for the treatment of highly refractory haematological malignancies, Dr Kylee MacLachlan, University of Melbourne. (Clinical PhD scholarship)
Cellular therapies for B-cell malignancies and post-transplant viral infections, Dr David Bishop, University of Sydney. (Clinical PhD scholarship)
Characterising genetic factors that contribute to relapses in acute myeloid leukaemia, Dr Chen Hsung Edward Chew, WEHI. (Clinical PhD scholarship)
Determining the role of the pro-survival Bcl-2 family member A2 in lymphoma and leukaemia, Robyn Schenk, WEHI. (PhD scholarship)
Role of dynein light chain in B-cell lymphoma onset and therapies, Lingli Li, St Vincent’s Institute. (PhD scholarship)
Cellular and molecular mediators of chronic graft versus host disease, Katie Lineburg, QIMR Berghofer. (PhD scholarship)
The molecular basis of Fanconi anaemia, a leukaemia predisposition syndrome, Julienne O’Rourke, St Vincent’s Institute. (PhD scholarship)
Investigating pre-existing and/or acquired resistance to novel Pol I transcription inhibitors for the treatment of hematologic malignancies, Donald Cameron, University of Melbourne. (PhD scholarship)
Regulation of MCL1 transcription and protein stability in myeloma and lymphoma cells, Dr Michael Sze Yuan Low, University of Melbourne. (PhD scholarship)

Targeting telomerase to eradicate leukaemia stem cells in acute myeloid leukaemia, Dr Steven Lane, QIMR. (Grant-in-aid)
Role of pro-survival BCL-2 proteins in acute myeloid leukaemia, T- cell acute lymphoblastic leukaemia and chronic myeloid leukaemia, Dr Stefan Glaser, WEHI. (Grant-in-aid)
Blood cancer survivorship, Professor Pam McGrath, University of Notre Dame Australia. (Grant-in-aid)
Pilot study to look at the feasibility of using remote vital sign monitoring app to improve the care of patients being treated at home with highly myelosuppressive chemotherapy, Dr Nigel Waterhouse, Mater Medical Research Institute. (Grant-in-aid)
Targeting stem cells in mouse model of T-cell acute lymphoblastic leukaemia, Dr Matthew McCormack and Dr Benjamin Shields, WEHI. (Grant-in-aid)
MLL fusion proteins: uncovering genetic and epigenetic mechanisms of leukemogenesis, Dr Margherita Ghisi, Peter MacCallum Cancer Centre. (Grant-in-aid)
Chair in Blood Cancer Research, Professor Maher Gandhi, The University of Queensland, Diamantina Institute. (Grant-in-aid)
Regulation of B-cell survival and migration by the oncogene c-Myb, Dr Kim Jacobson, WEHI. (Grant-in-aid)
Off the shelf T-cell expressing a chimeric antigen receptor targeting B-cell tumours, Dr Kenneth Micklethwaite, Westmead Millenium Institute. (Grant-in-aid)
Childhood Ph-like acute lymphoblastic leukaemia: improving diagnostic screening and therapeutic rationale, Associate Professor Deborah White and Associate Professor Charles Mullighan, University of Adelaide. (Grant-in-aid)
Elucidation of the mechanisms involved in the development of erytho-megakaryocytic leukaemia driven by the proto-oncogene ETS-related gene (ERG), Dr Catherine Carmichael and Dr Benjamin Kile, WEHI. (Grant-in-aid)
Identifying drivers of a stem cell-like program in leukaemic cells, Dr Ashwin Unnikrishnan, University of NSW. (Grant-in-aid)
Targeting the pro-survival machinery in acute myeloid leukaemia for therapeutic benefit, Professor Andrew Wei and Professor David Huang, Monash University (Grant-in-aid)
Characterisation of immune response in chronic myeloid leukaemia patient on nilotinib and interferon alpha, Dr Agnes Yong and Professor Timothy Hughes, ALLG. (Grant-in-aid)
Assessment of a genetic signature to predict chronic myeloid leukaemia disease progression, Dr Wendy Parker, Centre for Cancer Biology, Central Adelaide Local Health Network. (Postdoctoral fellowship)
Structural investigation of interleukin-3 receptor signalling for acute myeloid leukaemia therapeutics, Dr Sophie Broughton, St Vincent’s Institute of Medical Research. (Postdoctoral fellowship)
Exploiting novel mutations in high-risk childhood acute leukaemia with targeted therapy, Dr Santi Suryani, Children’s Cancer Institute. (Postdoctoral fellowship)
Mechanisms of antigen presentation following bone marrow transplantation graft versus host disease, Dr Motoko Koyama, QIMR Berghofer. (Postdoctoral fellowship)
Targeting epigenetic regulators in acute myeloid leukaemia, Dr Mark Dawson, University of Melbourne. (Senior research fellowship)
Defining the role of LYL1 and NG-kappaB in T-cell acute lymphoblastic leukaemia, Dr Sung Kai Chiu, Monash University. (Clinical PhD scholarship)
Investigating myeloid micro-environment effects on the epigenetic control of CD4+ T-cell polarisation, Dr Rachel Cooke, University of Melbourne. (Clinical PhD scholarship)
Therapeutic targeting of CDK9 and immune evasion in myelocytomatosis proto-oncogene (MYC)-driven B-cell lymphoma, Dr Gareth Gregory, University of Melbourne, Peter MacCallum Cancer Centre. (Clinical PhD scholarship)
Chromatin regulation of self-renewal in leukaemia cells, Dr Chun Yew Fong, University of Melbourne, Peter MacCallum Cancer Centre. (Clinical PhD scholarship)
Determining the role of mutant p53 in sustained growth and myelocytomatosis proto-oncogene (MYC)-driven lymphomas, Dr Brandon Aubrey, WEHI. (Clinical PhD scholarship)
Cytotoxic immune cells for anti-viral/tumour therapy in haematological malignancy, Dr Barbara Withers, University of Sydney, Westmead Millennium Institute. (Clinical PhD scholarship)
Anti-leukaemia effects of the type I and II interferons (graft versus host disease), Dr Andrea Henden, QIMR Berghofer. (Clinical PhD scholarship)
Regulators of epigenetic gene expression in haematopoiesis and leukaemia, Therese Vu, QIMR Berghofer. (PhD scholarship)
Combined epigenetic and immunomodulatory therapy for myelocytomatosis proto-oncogene (MYC)-driven lymphoma and myeloma, Simon Hogg, University of Melbourne, Peter MacCallum Cancer Centre. (PhD scholarship)
Roles of NF-kappa B transcription factors in acute myeloid leukaemia, Hui Peng Lim, Monash University. (PhD scholarship)
Mutation profiling of megakaryocytes in myeloproliferative neoplasms, Jacques Malherbe, University of WA. (Honours scholarship)
Dysregulated cell signalling in megakaryocytes in myeloproliferative neoplasms, Ayesha Arshad, University of WA. (Honours scholarship)

Assessment of biomarkers of response and the development of novel treatment strategies to improve molecular response in chronic myeloid leukaemia, Dr David Yeung, SA Pathology. (Clinical PhD scholarship)
Is elevated N-cadherin expression a poor prognostic indication in myeloma patients, Professor Andrew Zannettino, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
The role of PI3CA mutation in driving haematological malignancy, Associate Professor Wayne Phillips, Peter MacCallum Cancer Centre. (Grant-in-aid)
Targeted disease-initiating stem cells in myeloproliferative neoplasms, Dr Steven Lane, Professor Geoff Hill, Dr Ann Mullaly and Dr Florian Heidel, QIMR Berghofer. (Grant-in-aid)
RNA polymerase I as a new target for the treatment of haematological malignancies, Associate Professor Ross Hannan, Peter MacCallum Cancer Centre. (Grant-in-aid)
Finding new therapeutics to target T-cell leukaemia initiating cells, Dr Matthew McCormack and Dr Benjamin Shields, WEHI. (Grant-in-aid)
The role of the pro-survival BCL-2 family member A1 in the development of lymphomas, Dr Marco Herold, Professor Andreas Strasser and Dr Gemma Kelly, WEHI. (Grant-in-aid)
The immunopathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly, Associate Professor Maher Gandhi, QIMR Berghofer. (Grant-in-aid)
Generic variation and risk of infection in children following stem cell transplant, Dr Lesley Ashton, Professor Michelle Haber and Dr Tracey O’Brien, Children’s Cancer Institute Australia. (Grant-in-aid)
Evaluating the efficacy and tolerability of targeting pro-survival Mcl-1 in vivo, Dr Kylie Mason, Dr Toru Okamoto, Professor Andrew Roberts and Professor David Huang, WEHI. (Grant-in-aid)
Retinoid signalling in T-cell development and leukaemia, Dr David Izon and Associate Professor Louise Purton, St Vincent’s Institute. (Grant-in-aid)
Predicting clinical success of a novel inhibitor of ribosomal RNA synthesis, Dr Megan Bywater, Peter MacCallum Cancer Centre. (Postdoctoral fellowship)
Quality of care in blood cancer: patients’ perceptions, Dr Flora Tzelepis, University of Newcastle. (Postdoctoral fellowship)
The role of ETS-related gene (ERG) transcription factor in the development of leukaemia, Dr Sophie Hye Suk Lee, WEHI. (Clinical PhD scholarship)
T-cell therapy for infection and cancer prevention post allogenic stem cell transplant, Dr Chun Kei Kris Ma, University of Sydney. (Clinical PhD scholarship)
Therapeutic studies to target signal transduction pathways in acute myeloid leukaemia, Dr Peter Tan, Monash University. (Clinical PhD scholarship)
Molecular determinants of nilotinib treatments in patients with chronic myeloid leukaemia, Dr Jane Gordon, Centenary Institute. (Clinical PhD scholarship)
Investigating myeloma microenvironment effects on T-cell polarisation and function, Nicholas Gheradin, University of Melbourne, Peter MacCallum Cancer Centre. (PhD scholarship)
Optimisation of CD8+ dendritic cells cross presentation for enhances graft versus leukaemia effects following transplant, Melody Cheong Shuk Shien, QIMR Berghofer. (PhD scholarship)
The role of Ikaros in acute lymphoblastic leukaemia treatment resistance, Matthew Witkowski, WEHI. (PhD scholarship)
Conceptualising meaning in life: the experience of young adult cancer survivors, Danielle Tindle, Queensland University of Technology. (PhD scholarship)
The role of ADAR1 in haematopoiesis and leukaemia, Brian Liddicoat, St Vincent’s Institute. (PhD scholarship)

Role of CD123 in myelodysplastic neoplasms and acute myeloid leukaemia, Professor Angel Lopez, University of Adelaide. (Priority-driven Collaborative Cancer Research Scheme)
The role of Gpsm2 in self-renewal of haematopoietic and leukaemia stem cells, Dr Sarah Russell and Dr Stephen Ting, Peter MacCallum Cancer Centre and Swinburne University of Technology. (Grant-in-aid)
Epigenomic profiling of B-cell lymphoma progression and response to histone deacetylase inhibitor treatment, Dr Richard Tothill, Associate Professor Ross Hannan, Associate Professor Ricky Johnstone and Dr Gretchen Poortinga, Peter MacCallum Cancer Centre. (Grant-in-aid)
Predicting the in vivo sensitivity of paediatric acute lymphoblastic leukaemia to BH-3 mimetic drugs (ABT-263 Navitoclax), Associate Professor Richard Lock, Dr Warren Kaplan and Dr Hernan Carol, Children’s Cancer Institute and University of NSW. (Grant-in-aid)
Dequalinium chloride as a targeted therapy for acute myeloid leukaemia, Professor Richard D’Andrea, Dr Ian Lewis, Dr Jason Powell, Dr Anna Brown, University of Adelaide. (Grant-in-aid)
Patterns of differentially abundant proteins on progressive chronic lymphocytic leukaemia, Professor Richard Christopherson and Associate Professor Stephen Mulligan, University of Sydney. (Grant-in-aid)
MM13: Phase III randomised trial of melphalan and dexamethasone =/- bortezomib in AL amyloidosis, Professor Peter Mollee, Dr Hugh Goodman, Professor David Gottlieb and Professor David Booth, ALLG, Princess Alexandra Hospital. (Grant-in-aid)
Contribution of apoptosis to clearance of haematopoietic malignancies by cytotoxic lymphocytes, Dr Nigel Waterhouse, Mater Medical Research Institute. (Grant-in-aid)
The role of thymic self-renewal in causing T-cell acute lymphoblastic leukaemia, Dr Matthew McCormack and Dr Benjamin Shields, WEHI. (Grant-in-aid)
Targeting novel cell survival programs in acute myeloid leukaemia regulated by PI3-K, Dr Mark Guthridge, Australian Centre for Blood Diseases, Monash University. (Grant-in-aid)
Identification of susceptibility genes for familial haematological malignancies, Dr Joanne Dickinson, Menzies Research Institute. (Grant-in-aid)
Immune suppression in graft versus host disease, Professor Geoff Hill, Dr Kelli MacDonald and Dr Kate Markey, QIMR Berghofer. (Grant-in-aid)
Developing a gene signature to predict the optimal front line kinase inhibitor for chronic phase, chronic myeloid leukaemia patients, Dr Deborah White and Professor Timothy Hughes, Centre for Cancer Biology. (Grant-in-aid)
Autologous cellular therapy for rapid immune reconstitution in patients with chronic lymphocytic leukaemia receiving immunosuppressive chemotherapy, Professor David Gottlieb, Westmead. (Grant-in-aid)
Small molecule inhibitors of protein arginine methyltransferase 5 (PRMT5) for chronic lymphocytic leukaemia, Associate Professor David Curtis and Professor Stephen Jane, Monash University. (Grant-in-aid)
Improving prognostic analysis of chronic lymphocytic leukaemia through assessment of DNA repair, Associate Professor Bryone Kuss and Dr Scott Grist, Flinders University. (Grant-in-aid)
Impaired double strand break repair as a mechanism of relapse following chemotherapy, Associate Professor Bryone Kuss and Dr Scott Grist, Flinders University. (Grant-in-aid)
Inositol phosphoinositide regulation of PI3-K activity: defining their role as collaborators in leukaemogenesis, Professor Andrew Wei and Professor Christina Mitchell, Alfred Hospital, Monash University. (Grant-in-aid)
AMLM16 phase 2 randomised study investigating the FLT3 inhibitor Srafenib in sequence after intensive chemotherapy for untreated adult acute myeloid leukaemia harbouring FLT3 mutations, Professor Andrew Wei, Monash University. (Grant-in-aid)
Genetic co-cooperativity and the role of transcription factors in malignant haematological disorders, Associate Professor Ashley Ng, WEHI. (Postdoctoral fellowship)
The role of sotepontin as a cell survival factor in acute myeloid leukaemia, Dr Tse-Chieh Teh, Monash University. (Clinical PhD scholarship)
Therapeutic inhibition of the cell cycle checkpoints mediated by CHK1, Dr Jake Shortt, Peter MacCallum Cancer Centre. (Clinical PhD scholarship)
Ineffective haematopoiesis and the role of apoptosis in myelodysplastic neoplasms, Dr Andrew Guirguis, Monash University. (Clinical PhD scholarship)
The role of IL-3 receptor on acute myeloid leukaemia stem cells, Nicole Christie, Centre for Cancer Biology, SA Pathology. (PhD scholarship)
Impact of MCL-1 on the dev of acute myeloid leukaemia and its resistance to therapy, Natasha Anstee, WEHI. (PhD scholarship)
Cooperating oncogenic lesions in myelocytomatosis proto-oncogene (MYC-driven) lymphoma, Marcus Lefebure, Peter MacCallum Cancer Centre. (PhD scholarship)
Inhibiting the PI3K pathway induces B-cell lymphoma death via ribosome biogenesis, Jennifer Devlin, Peter MacCallum Cancer Centre. (PhD scholarship)
Roles of the bone marrow micro environment in the regulation of blood disease, Hui Peng Lim, University of Melbourne. (PhD scholarship)
MLF1 regulation of the haematopoietic stem cell compartment, Tara Nababan, University of WA. (Honours scholarship)

Study of genes that cause chronic lymphocytic leukaemia, Dr Steven Fuller, Professor James Wiley, Professor Hamish Scott, Dr Melanie Bahlo and Dr Christopher Hahn, University of Sydney. (Grant-in-aid)
Understanding how blood and leukaemia stem cells function, Dr Stephen Ting and Dr Sarah Russell, Swinburne University of Technology. (Grant-in-aid)
Regulation of vascular endothelial growth factor (VEGF) on human dendritic cells in multiple myeloma infiltrated bone marrow, Dr Slavica Vuckovic and Dr Laurence Catley, Mater Medical Research Institute. (Grant-in-aid)
A new chronic lymphocytic leukaemia model that aids better understanding of disease and how to treat it effectively, Dr Paul Neeson and Associate Professor David Ritchie, University of Melbourne. (Grant-in-aid)
Blocking HOX genes to treat leukaemia, Associate Professor Paul Ekert, Royal Children’s Hospital. (Grant-in-aid)
Helping blood cell number recover after transplantation or chemotherapy, Dr Louise Purton and Dr Maria Askmyr, St Vincent’s Institute. (Grant-in-aid)
Promoting cell death to improve treatment of chronic lymphocytic leukaemia (navitoclax), Dr Kylie Mason, Professor Andrew Roberts, and Dr David Huang, WEHI. (Grant-in-aid)
Randomised phase III trial to assess response adapted therapy using positron emission tomography (PET) in newly diagnosed advanced Hodgkin lymphoma, Professor John Seymour, Peter MacCallum Cancer Centre. (Priority-driven Collaborative Cancer Research Scheme)
Do leukemic cells adopt blood stem cell properties to induce leukaemia? Dr John Pimanda, Prince of Wales Clinical School. (Grant-in-aid)
Methods to prevent graft versus host disease after transplantation, Dr Hannah Cullup, Mater Medical Research Institute. (Grant-in-aid)
A novel agent targeting the HSP90 protein in chronic lymphocytic leukaemia, Dr Giles Best and Associate Professor Stephen Mulligan, Kolling Institute, Royal North Shore Hospital. (Grant-in-aid)
Novel growth factors in chronic lymphocytic leukaemia, Associate Professor Devinder Gill and Dr Nigel McMillan, Princess Alexandra Hospital. (Grant-in-aid)
Using the immune system against chronic lymphocytic leukaemia, Associate Professor David Ritchie and Dr Paul Neeson, University of Melbourne. (Grant-in-aid)
Definition of the mechanism by which caspase-2 suppresses lymphomagenesis, Dr Christine Hawkins, La Trobe University. (Grant-in-aid)
Cell cycle regulation in haemopoietic stem cells and MDS, Dr Carl Walkley, St Vincent’s Institute. (Philip Desbrow Senior Research Fellow)
Psychosocial outcomes in blood cancer: the role of treatment centre structures and processes, Dr Tara Clinton-McHarg, University of Newcastle. (Postdoctoral fellowship)
Understanding the molecular basis of lymphoma cell death, Dr Mark McKenzie, WEHI. (Postdoctoral fellowship)
The risk of haematopoietic cancer in people hospitalised with an autoimmune disease, Dr Marina Van Leeuween, University of NSW. (Postdoctoral fellowship)
New therapies for acute lymphoblastic leukaemia, Dr Craig Wallington-Beddoe, Westmead Millenium Institute. (Clinical PhD scholarship)
Identification of genetic changes in aggressive B-cell lymphomas and impact on tumour growth, Dr Anna Johnston, John Curtin School of Medical Research ANU. (Clinical PhD scholarship)
Where to after treatment? A new way to support young people with cancer and their parents, Ursula Sansom-Daly, University of NSW. (PhD scholarship)
EpHA proteins may be therapy targets in Leukaemia, Sara Charmsaz, QIMR Berghofer. (PhD scholarship)
Eradication of leukaemic cells using therapy combination in chronic myeloid leukaemia, Lisa Schafranek, SA Pathology, University of Adelaide. (PhD scholarship)
Understanding the molecular mechanisms that regulate blood stem cell activity, Leila Varghese, WEHI. (PhD scholarship)
Targeting signalling in acute lymphoblastic leukaemia, Jacky Wong, Westmead Millenium Institute. (PhD scholarship)
Defining the unique characteristics of chronic phase, chronic myeloid leukaemia patients that respond poorly to Imatinib, Dale Watkins, SA Pathology, University of Adelaide. (PhD scholarship)
Analysis of therapeutic agents to kill leukaemia cells via notch signalling, Timothy Colgan, University of WA. (Honours scholarship)
Measurement of blood markers to determine cell therapy treatment of graft versus host disease, Kaija Strautins, Royal Perth Hospital. (Honours scholarship)

The use of donor immune cells to fight viral infections in recipients of blood stem cell transplants, Dr Emily Blyth, Westmead Millenium Institute. (Clinical fellowship)
Development of drugs to block the MYB cancer gene in human leukaemia, Professor Tom Gonda, University of Queensland, Diamantina Institute. (Grant-in-aid)
Role of myeloid leukaemia factor 1 in stem cells, Professor Svend Klinken and Dr Louise Winteringham, University of WA. (Grant-in-aid)
Developing new treatments for blood cancer, Associate Professor Ricky Johnstone and Professor Mark Smyth, Peter MacCallum Cancer Centre (Grant-in-aid)
Determining the cause of T-cell acute lymphoblastic leukaemia, Dr Matthew McCormack and Dr David Curtis, Royal Melbourne Hospital. (Grant-in-aid)
Understanding how blood cell disease form, Professor Louise Purton and Dr Maria Askmyr, St Vincent’s Institute. (Grant-in-aid)
The risk of developing a second cancer after leukaemia or lymphoma, Associate Professor Lin Fritshci, University of WA. (Grant-in-aid)
Developing effective therapy for chronic graft versus host disease, Professor Geoff Hill and Dr Kelli MacDonald, QIMR Berghofer. (Grant-in-aid)
Investigating the factors that cause and influence the outcome of childhood leukaemias, Associate Professor David Ashley, Dr Nicholas Wong, Dr Richard Saffery and Dr Jeff Craig, Murdoch Children’s Research Institute. (Grant-in-aid)
Targeting increased PI3K and the bone marrow microenvironment for therapeutic benefit in leukaemia, Dr Andrew Wei and Professor Shaun Jackson, Monash University. (Grant-in-aid)
Methods to precent graft versus host disease after transplantation, Associate Professor Alison Rice, Dr David Munster and Professor Derek Hart, Mater Medical Research Institute. (Grant-in-aid)
Bench to bedside – studies with a novel therapy in adult and childhood cancer, Dr Seong Lin Khaw, Royal Melbourne Hospital. (Clinical fellowship)
New strategies to assist in the management of aggressive lymphoma, Dr Colm Keane, Princess Alexandra Hospital. (Clinical fellowship)
Investigation of the physiological role of the transcriptional factor ERG in haematopoietic development and disease, Dr Catherine Carmichael, WEHI. (Postdoctoral fellowship)
Understanding and manipulating cell death to treat blood cancers, Dr Erinna Faith Lee, WEHI. (Postdoctoral fellowship)
Pathogenesis of myelodysplastic neoplasms – identifying genes that are abnormally switched off in myelodysplastic neoplasms, Dr John Pimanda, University of NSW. (Career establishment grant)
Mechanisms of drug resistance in childhood leukaemia, Dr Vivek Bhadri, Children’s Cancer Institute of Australia. (Clinical PhD scholarship)
Understanding cancers of the blood, Swee Heng Pang, WEHI. PhD scholarship)
Molecular regulation of cell death and implications in platelet production, Michael White, WEHI. (PhD scholarship)
Studies of cellular transport of nilotinib, Laura Eadie, SA Pathology, University of Adelaide. (PhD scholarship)
New strategies for the treatment and prevention of Hodgkin lymphoma, Kimberly Jones, QIMR Berghofer. (PhD scholarship)
Genes involved in acute myeloid leukaemia, Grace Liu, WEHI. (PhD scholarship)
To determine the role of Bok in programmed cell death and leukaemia development, Francine Ke, WEHI. (PhD scholarship)
The role of the innate immune system in cancer, Christopher Chan, Peter MacCallum Cancer Centre. (PhD scholarship)
Study of a bone marrow stromal cell in chronic lymphocytic leukaemia, Adrian Pannekoek, Royal Perth Hospital. (Honours scholarship)

Susceptibility to chronic lymphocytic leukaemia in an extended family pedigree, Dr James Wiley, University of Sydney. (Grant-in-aid)
Familial psychological adjustment and needs on childhood cancer treatment completion, Associate Professor Claire Wakefield, University of NSW. (Grant-in-aid)
Targeted modulation of antigen presenting cells in graft versus host disease, Renee Robb, QIMR Berghofer. (PhD scholarship)
Developing predictive assays to select second line therapy imatinib resistant chronic myeloid leukaemia, Professor Timothy Hughes, Dr Susan Branford and Dr Deborah White, SA Pathology, University of Adelaide. (Grant-in-aid)
A new oncogene in acute myeloid leukaemia and myelodysplastic neoplasms, Dr Ruth MacKinnon, St Vincent’s Hospital. (Grant-in-aid)
Improving treatment outcomes for infants with acute lymphoblastic leukaemia, Dr Michelle Henderson, Children’s Cancer Institute. (Grant-in-aid)
An analysis of acute myeloid leukaemia in Western Australia from 1991 to 2005, Dr Mathew Wright, Royal Perth Hospital. (Grant-in-aid)
A novel mechanism of immunosuppression in B-cell lymphomas, Associate Professor Maher Gandhi, QIMR Berghofer. (Grant-in-aid)
Molecular prognostication in chronic lymphocytic leukaemia, Dr Raymond Banh, Princess Alexandra Hospital. (Clinical fellowship)
New therapeutic approach in acute leukaemia and transplant and graft versus host disease, Dr Simon Zhao-Xiong He, Melbourne Health. (Clinical fellowship)
Gene trap mutagenesis a function screen to identify gene associated with glucocorticoid resistance in acute lymphoblastic leukaemia, Scott Brown, Children’s Cancer Institute of Australia. (PhD scholarship)
Development of dendritic cell biomarker antibodies and application in leukaemia, Therese Seldon, Mater Research Institute. (PhD scholarship)
The impact of BH3-only genes on the response of murine lymphoma to anti-cancer therapy, Lina Happo, WEHI. (PhD scholarship)
Targeting MYB in human leukaemia, Diwakar Pattabiraman, University of Queensland, Diamantina Institute. (PhD scholarship)
Targeting a deregulated cell survival switch in chronic myeloid leukaemia cells, Hui Peng Lim, Institute of Medical and Veterinary Science. (Honours scholarship)
Role of DNAM-1 in NK cell-mediated tumour control, Christopher Chan, Peter MacCallum Cancer Centre. (Honours scholarship)

Restoring immunity against viruses after bone marrow transplantation, Dr Siok-Keen-Tey, QIMR Berghofer. (Clinical fellowship)
Can the environment cause childhood leukaemia? If so how and when does this occur? Dr Nicholas Wong. (Postdoctoral fellowship)
Role of pentoxifylline (trental) on anaemia and hypoferritinaemia in myeloma, Dr Stephanie P’ng. (New investigator grant)
Valproic acid and cytarabine therapy for elderly or relapsed acute myeloid leukaemia, Dr Peter Mollee and Dr Nigel McMillan, Princess Alexandra Hospital. (Grant-in-aid)
Acute myeloid leukaemia M13 – High dose cytosine arabinose and fludarabine without anthracycline for core-binding factor acute myeloid leukaemia, Dr Paula Marlton, ALLG. (Grant-in-aid)
Targeting drug resistance in childhood leukaemia, Associate Professor Maria Kavallaris, University of NSW. (Grant-in-aid)
Indirect antigen presentation and graft vs leukaemia effects after transplantation, Associate Professor Geoff Hill and Dr Kelli MacDonald, QIMR Berghofer. (Grant-in-aid)
Improving the treatment of refectory graft versus host disease using mesenchymal stromal cells, Dr Stephen Larsen, Royal Prince Alfred Hospital. (Career establishment grant)
Developing a vaccine strategy to treat EBV-associated HL, Dr Corey Smith, QIMR Berghofer (Postdoctoral fellowship)
Novel disease markers and therapeutic targets in B-cell chronic lymphocytic leukaemia, Melanie Sulda, Flinders University. (PhD scholarship)
Factors which control targeted drug uptake into chronic myeloid leukaemia cells, Jane Engler, Institute of Medical and Veterinary Science. (PhD scholarship)
Investigation of Klf5, a potentially new leukaemia causing gene, Subhobrata Das, University of Adelaide. (Honours scholarship)
Mesenchymal stem cells for allogeneic stem cell transplantation, Dana Ihdayhid, Curtin University and Royal Perth Hospital. (Honours scholarship)

The effect of combining specific anti-cancer drug therapies as treatment for patients with leukaemia and lymphoma, Dr Ricky Johnstone, Peter MacCallum Cancer Centre. (Grant-in-aid)
Molecular targeted therapy in childhood acute lymphoblastic leukaemia, Dr Richard Lock and Associate Professor Glen Marshall, Children’s Cancer. (Grant-in-aid)
Genetic control of white blood cell production that may have a role in acute and chronic leukaemias, Professor John Rasko, Centenary Institute of Cancer Medicine and Cell Biology. (Grant-in-aid)
A pooled analysis of studies for immune risk factors for non-Hodgkin lymphoma, Associate Professor Andrew Grulich and Dr Claire Vajdic, National Centre in HIV Epidemiology and Clinical Research. (Grant-in-aid)
Blimp-1 regulates lymphocyte differentiation and leukaemogenesis, Dr Axel Kallies, WEHI. (Postdoctoral fellowship)
Targeted therapy and new diagnostic strategies for the management of the chronic myeloproliferative disorders, Dr William Stevenson, Royal North Shore Hospital. (Career establishment grant)
Characterisation of leukaemic chronic myeloid leukaemia cells remaining after treatment, Dr David Ross, Institute of Medical and Veterinary Science. (Clinical PhD scholarship)
The role of lineage and maturity in determining in vitro sensitivity to kinase inhibitors in chronic phase chronic myeloid leukaemia, Jane Engler, Institute of Medical and Veterinary Science. (Honours scholarship)

MM8 amyloidosis clinical trial: a Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis, Dr Peter Mollee, ALLG. (Grant-in-aid)
Glucocorticoid resistance mechanisms in childhood acute lymphoblastic leukaemia, Dr Richard Lock, Dr Maria Kavallaris and Associate Professor Ursula Kees, Children’s Cancer Institute. (Grant-in-aid)
Mechanisms of drug resistance in acute myeloid leukaemia, Professor Leonie Ashman, University of Newcastle. (Grant-in-aid)
Micro RNAs in primate haematopoiesis, Professor John Rasko, Centenary Institute of Cancer Medicine and Cell Biology. (Grant-in-aid)
Development of anti-T acute lymphoblastic leukaemia reagents, Dr Jacqueline Matthews, Dr Joel Mackay and Associate Professor Merlin Crossley, University of Sydney. (Grant-in-aid)
The Australian familial haematological study, Dr Graeme Suthers and Associate Professor Richard D’Andrea, Women’s and Children’s Hospital Adelaide. (Grant-in-aid)
Prevention of leukaemia relapse after stem cell transplantation, Dr Geoff Hill, QIMR Berghofer. (Grant-in-aid)
Use of T-cells for immunotherapy of infections post-allogeneic stem cell transplant, Dr Kenneth Micklethwaite, Westmead Hospital. (Clinical fellowship)
The role of apoptosis in suppression of myeloid leukaemia by PU.1, Dr Wendy Cook, University of Melbourne. (Greg Johnson Memorial Postdoctoral Fellowship)
Identification of oncogene from myeloid leukaemia by retroviral expression cloning, Dr Anna Brown, Child Health Research Institute. (Postdoctoral fellowship)
Assessing the apoptotic and therapeutic properties of histone deacetylases inhibitors in mouse models of lymphoma, Leigh Ellis, Peter MacCallum Cancer Centre. (PhD scholarship)
Further definition of the tumour antigen targets of dendritic cell-based immunotherapy in multiple myeloma, Jennifer Freeman, Mater Medical Research Institute. (PhD scholarship)
Potential new target molecules for acute myeloid leukaemia treatment – the role of the 35 -L5 molecule, Courtney Modra, Mater Medical Research Institute. (PhD scholarship)
Proof of principle for the use of cytotoxic T-lymphocytes induced by RNA loaded CD34+ stem cell derived dendritic cells to eradicate leukaemia post transplantation, Andy Hsu, Mater Medical Research Institute. (PhD scholarship)
The role of the protein p202 in myeloid cell differentiation, Yi-No (Enoch) Ko, Peter MacCallum Cancer Centre. (Honours scholarship)
The roles of FAM and beta-catenin in regulating the properties of some haemopoietic cells in vitro, Kate Jarman, Child Health Research Institute. (Honours scholarship)
The development of inhibitors of BCL-2-family proteins as potential therapeutic agents in leukaemia and lymphoma, Jessica Bird, James Cook University. (Honours scholarship)
The role of pRb in erythropoiesis, Catherine King, Peter MacCallum Cancer Centre. (Honours scholarship)

Stratification of high-risk acute lymphoblastic leukaemia patients based on minimal residual disease, Professor Murray Norris, Dr Rosemary Sutton, Dr Luciano Dalla Pozza and Professor Michelle Haber, Children’s Cancer Institute. (Grant-in-aid)
Molecular determinants of microtubule target drug response in childhood leukaemia, Dr Maria Kavallaris and Dr Richard Lock, Children’s Cancer Institute. (Grant-in-aid)
Generation of immune anti-leukaemia effect using gene transfer to human leukaemia cells, Associate Professor David Gottlieb and Associate Professor John Rasko, Western Sydney Area Health Service. (Grant-in-aid)
Novel complexes of gallium as potent anti-leukaemia and lymphoma agents, Professor Des Richardson and Dr Richard Lock, Children’s Cancer Institute. (Grant-in-aid)
CD44v6 ligand involved in aggressiveness of childhood acute lymphoblastic leukaemia, Dr Linda Bendall and Professor Kenneth Bradstock, Westmead Hospital. (Grant-in-aid)
Investigating the role of cell death inducing molecules in lymphoma and leukaemia, Dr Lisa Sedger and Dr Linda Bendall, Westmead Hospital. (Grant-in-aid)
A genetic variation associated with chronic lymphocytic leukaemia, Professor James Wiley, Nepean Hospital. (Grant-in-aid)

Past research

Completed research projects

Need help?